Patents by Inventor David L. Smiley

David L. Smiley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190374335
    Abstract: Delivery devices for delivering an ophthalmic device into an eye. In some embodiments the delivery devices are adapted to deliver an intraocular lens into an eye.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 12, 2019
    Applicant: PowerVision, Inc.
    Inventors: Terah Whiting SMILEY, John A. SCHOLL, David John SMITH, Russell J. REDMOND, Derek L. MORAN, Barry CHESKIN, John REGGIE, Gregory Vinton MATTHEWS, Claudio ARGENTO
  • Patent number: 10350060
    Abstract: Delivery devices for delivering an ophthalmic device into an eye. In some embodiments the delivery devices are adapted to deliver an intraocular lens into an eye.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 16, 2019
    Assignee: PowerVision, Inc.
    Inventors: Terah Whiting Smiley, John A. Scholl, David John Smith, Russell J. Redmond, Derek L. Moran, Barry Cheskin, John Reggie, Gregory Vinton Matthews, Claudio Argento
  • Publication number: 20190127433
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • Patent number: 10232020
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, John P. Mayer, David L. Smiley, Fa Liu
  • Patent number: 10174093
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: January 8, 2019
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Publication number: 20180105569
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Inventors: Richard D. DiMARCHI, David L. SMILEY, Konrad H. BLEICHER, Eric A. KITAS
  • Patent number: 9868772
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 16, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley, Konrad H. Bleicher, Eric A. Kitas
  • Publication number: 20170349642
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: August 7, 2017
    Publication date: December 7, 2017
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • Publication number: 20170281788
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.
    Type: Application
    Filed: September 23, 2015
    Publication date: October 5, 2017
    Inventors: Richard D. DIMARCHI, John P. MAYER, David L. SMILEY, Fa LIU
  • Patent number: 9758562
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 12, 2017
    Assignee: Indiana University and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 9447162
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
  • Patent number: 9309301
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: April 12, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley, Bin S. Yang
  • Publication number: 20150376256
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 31, 2015
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • Publication number: 20150368310
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 24, 2015
    Inventors: Richard D. Dimarchi, David L. Smiley, Konrad H. Bleicher, Eric A. Kitas
  • Patent number: 9156902
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: October 13, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Publication number: 20150126440
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Application
    Filed: November 7, 2014
    Publication date: May 7, 2015
    Inventors: Jonathan DAY, James PATTERSON, Joseph CHABENNE, Maria DiMARCHI, David L. SMILEY, Richard D. DiMARCHI
  • Patent number: 9018164
    Abstract: Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 8900593
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 2, 2014
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
  • Publication number: 20140221283
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: June 12, 2012
    Publication date: August 7, 2014
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley
  • Publication number: 20140206607
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: June 12, 2012
    Publication date: July 24, 2014
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. Dimarchi, David L. Smiley, Bin S. Yang